Company Filing History:
1 out of 5 
1 out of 2 Years Active: 2007
Title: Innovations by Anthony J F d′Apice in Xenotransplantation
Introduction
Anthony J F d′Apice, based in Balwyn, Australia, is a notable inventor recognized for his significant contributions to the field of xenotransplantation. His innovation addresses a critical issue in transplant medicine—hyperacute rejection, which is a significant barrier to the successful transplantation of animal organs into humans.
Latest Patents
Anthony J F d′Apice holds a patent for "Materials and methods for management of hyperacute rejection in human xenotransplantation". This invention focuses on the role of pre-formed xenoantibodies in human xenotransplantation and introduces materials and methods for their removal or neutralization. It further addresses the challenge posed by specific epitopes in donor organs recognized by these antibodies, which stem from the activity of the enzyme α-1,3 galactosyltransferase. The patent details the porcine gene encoding this enzyme and outlines methods for knocking out the gene in mammalian cells and embryos. It also presents a novel leukemia inhibitory factor (T-LIF) that enables the maintenance of embryonic stem cells and primordial germ cells in culture.
Career Highlights
Anthony J F d′Apice's career includes significant roles at notable organizations such as Bresagen, Inc. and St. Vincent's Hospital. His work has directly contributed to advancements in medical science, particularly in the delicate and high-stakes area of organ transplantation, which can save countless lives when perfected.
Collaborations
Throughout his career, Anthony has collaborated with distinguished colleagues, including Martin J Pearse and Allan J Robins. These partnerships have fostered an environment of innovation and development, essential for tackling complex medical challenges.
Conclusion
Anthony J F d′Apice's work exemplifies the critical intersection of innovation and medical science. His patent demonstrates a proactive approach to solving the challenges of xenotransplantation. As the field progresses, contributions like his will remain integral to advancing transplant technologies and improving patient outcomes.